Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hierarchically Chiral Silver Nanoclusters Mediated Enantioselective Glutathione Depletion and Intracellular Self-Assembly for Enhanced Anticancer Therapy.

Angewandte Chemie (International ed. in English)·2026

Same author

Host ATR-vimentin hijacking to membrane-bound and membrane-less viral replication organelles fuels RNA virus propagation.

Science bulletin·2026

Same author

Overcoming Scale Variations and Occlusions in Aerial Detection: A Context-Aware DEIM Framework.

Sensors (Basel, Switzerland)·2026

Same author

Evaluation of INR101, a PSMA-Targeted <sup>18</sup>F PET Tracer, for suspected prostate cancer: A multicenter phase I/IIa trial with histopathologic confirmation.

EJNMMI research·2025

Same author

A single-center, randomized, double-blind, positive-controlled, phase IV clinical trial to assess the immunogenicity and safety of adsorbed tetanus toxoid vaccine in individuals aged ≥16 years.

Human immunology·2025

Same author

¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT.

European journal of nuclear medicine and molecular imaging·2025

Same journal

Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis.

Chinese clinical oncology·2026

Same journal

Can recurrence-free survival replace overall survival for resectable esophageal cancer?

Chinese clinical oncology·2026

Same journal

Venetoclax with intensive chemotherapy in acute myeloid leukemia.

Chinese clinical oncology·2026

Same journal

Network pharmacology of Sijunzi decoction in pancreatic cancer.

Chinese clinical oncology·2026

Same journal

Adjuvant CDK4/6 inhibitors and novel therapies in early breast cancer: lessons from monarchE overall survival data.

Chinese clinical oncology·2026

Same journal

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Chinese clinical oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 15, 2026

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

PET/CT: appropriate application in lymphoma.

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China. xuejuan_wang@hotmail.com.

Chinese Clinical Oncology

|April 6, 2015

Summary

This summary is machine-generated.

Positron emission tomography/computed tomography (PET/CT) is a sensitive tool for lymphoma. This review clarifies its appropriate use, prognostic value, and PET/CT-navigated applications in managing Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Keywords:

Positron emission tomography (PET)computed tomography (CT)lymphoma

More Related Videos

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Experiment Videos

Last Updated: Apr 15, 2026

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Area of Science:

Oncology
Radiology
Nuclear Medicine

Background:

Positron emission tomography (PET) integrated with computed tomography (CT) offers combined metabolic and morphologic insights.
PET/CT is the leading imaging modality for diagnosing and monitoring Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Purpose of the Study:

To provide a comprehensive review of the current applications of 18F-FDG PET/CT in lymphoma management.
To address controversies and clarify questions regarding the prognostic value of interim PET/CT and PET/CT-navigated treatment strategies.

Main Methods:

Literature review of studies on 18F-FDG PET/CT in lymphoma.
Analysis of current guidelines and expert opinions on PET/CT utilization in HL and NHL.

Main Results:

PET/CT is established for staging, response assessment, and end-of-treatment evaluation in most lymphoma subtypes.
The prognostic significance of interim PET/CT remains a subject of debate.
Clarification is provided on the evolving role of PET/CT in guiding therapeutic decisions.

Conclusions:

18F-FDG PET/CT is a crucial tool in lymphoma care, offering significant diagnostic and prognostic information.
Further research is needed to standardize interim PET/CT interpretation and optimize PET/CT-navigated treatment protocols.
This review aims to guide clinicians in the appropriate and effective use of PET/CT for optimal patient outcomes in lymphoma.